SARS-CoV-2 August 2025 Update: BioGX Confirms Detection of Emerging NB.1.8.1, LP.8.1, XEC, XFG, XFC, JN.1 and LF.7.9 Omicron Subvariants

BioGX continuously monitors the evolution of SARS-CoV-2 variants to ensure our market leading SARS-CoV-2 real-time PCR tests will continue to detect emerging variants. Specifically, variants that belong to clades NB.1.8.1, LP.8.1, XEC, XFG, XFC, JN.1 and LF.7.9.

BioGX has performed in-silico analysis of complete high coverage Omicron genomes of the following sublineages in the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV™ database as of 18 July 2025 (Table 1).

Sequence analysis of the variant genomes was compared against the SARS-CoV-2 reference genome to identify any mutations within the regions of the nucleocapsid (N-gene) targeted by BioGX products.

Based on in-silico analysis conducted on 18 July 2025, the nucleotide mutations present in NB.1.8.1, LP.8.1, XEC, XFG, XFC, JN.1 and LF.7.9 clades will not affect the detection capability of the BioGX portfolio of SARS-CoV-2 real-time PCR tests targeting the N-gene and all variants analyzed will be detected.

BioGX continues to monitor emerging SARS-CoV-2 lineage variants and any mutations with the potential to impact performance.

Table 1. Summary of SARS-CoV-2 variant (omicron sublineage) complete high coverage sequences utilized for in-silico analysis.

Contact BioGX:

For any inquiries, please contact us by clicking this link

Learn more about pixl™ Real-time PCR Platform to improve your testing.

To order BioGX testing kits, please fill out the form here, and a product specialist will reach out to you. visit https://biogx.com/request-a-quote/